Advances in clinical and experimental medicine : official organ Wroclaw Medical University, cilt.30, 2021 (SCI-Expanded)
Background. Bevacizumab-induced vascular endothelial growth factor (VEGF) inhibition may lead to a decrease in adenosine triphosphate (ATP) levels, an increase in intracellular Na+ and Ca2+ concentrations and an increase in reactive oxygen species (ROS) generation, as well as to cell damage.